NCT01490632 2019-09-27A Phase 2b Study of Baricitinib in Participants With Moderate to Severe PsoriasisEli Lilly and CompanyPhase 2 Completed271 enrolled 32 charts
NCT01241591 2018-12-26A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque PsoriasisPfizerPhase 3 Completed1,101 enrolled 46 charts